FUROSEMIDE (furosemide) by Hikma is henle. First approved in 1981.
Drug data last refreshed 8h ago
Furosemide is a loop diuretic administered by injection that works by inhibiting sodium-potassium-chloride reabsorption in the thick ascending limb of the loop of Henle. It is indicated for heart failure, renal impairment, essential hypertension, and liver cirrhosis, with a primary mechanism of action independent of carbonic anhydrase or aldosterone inhibition.
As a mature, approaching LOE product with moderate competitive pressure (30), the brand team is likely focused on cost management and niche positioning rather than growth expansion.
Henle. The high degree of efficacy is largely due to this unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone.
Loop Diuretic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bumetanide vs. Furosemide in Cirrhosis
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
Worked on FUROSEMIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on furosemide offers stable but limited career growth as a mature generic product with declining market positioning relative to newer therapies. Roles focus on market defense, cost management, and maintaining share in niche segments rather than expansion or innovation.